Bio & Pharma
MDimune signs research agreement with Australian National University
The Korean biotech company and Austrailian lab plan to find out the therapeutic effect of cell-derived vesicles
By Dec 07, 2022 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
S.Korea's LS Materials set to boost earnings ahead of IPO process
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
POSCO gears up for carbon-free steelmaking with hydrogen
MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research group within the Australian National University, to jointly research and develop macular degeneration treatments.
MDimune is a company that possesses cell-derived vesicles(CDVs) production technology that can be used as a drug delivery system by extruding cells.
The CVR Lab is a group that intensively studies age-related macular degeneration within the university, and has conducted initial animal experiments to see whether the CDVs provided by MDimune can be used for the treatment of age-related macular degeneration.
With the latest joint research pact, MDimune and the CVR Lab plan to find out the therapeutic effect of CDVs.
MDimune expects this collaboration to facilitate the commercialization of drug delivery systems.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Corporate strategyHyundai Glovis to spend $6.5 billion, seek M&As for expansion
Jun 28, 2024 (Gmt+09:00)
-
Korean chipmakersSouth Korea sets sights on fostering EDA tech to win HBM chip war
Jun 28, 2024 (Gmt+09:00)
Comment 0
LOG IN